(1S,2R)-2-(((benzyloxy)carbonyl)amino)cyclobutane-1-carboxylic acid | 517913-99-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S,2R)-2-(((benzyloxy)carbonyl)amino)cyclobutane-1-carboxylic acid
• 英文别名: (1S,2R)-2-{[(benzyloxy)carbonyl]amino}cyclobutane-1-carboxylic acid；(1S,2R)-2-(phenylmethoxycarbonylamino)cyclobutane-1-carboxylic acid
• CAS: 517913-99-4
• 化学式: C₁₃H₁₅NO₄
• 分子量: 249.266
• InChiKey: ZNRUEEQIUVKKBL-WDEREUQCSA-N

物化性质

• 沸点：
  464.9±44.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1S,2R)-2-(((benzyloxy)carbonyl)amino)cyclobutane-1-carboxylic acid 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲苯 为溶剂， 以71%的产率得到(1R,5S)-benzyl 3-oxo-2,4-diazabicyclo[3.2.0]heptane-2-carboxylate
  参考文献：
  名称：

  Synthesis and structural features of cyclobutane-containing chiral bicyclic ureas

  摘要：

  Efficient and stereoselective synthetic routes have been developed for the preparation of chiral N-mono-protected cyclobutane bicyclic ureas in which one of the NH groups is protected as a benzyl or tert-butyl carbamate. Ureas in both enantiomeric forms were obtained from a common chiral precursor via the selective manipulation of functional groups. These compounds have been subjected to a structural study in solution and in the solid state. NMR, IR and TEM techniques evidence a strong tendency to aggregation in solution giving regular assemblies, which is a result of intermolecular urea N-H center dot center dot center dot O=C hydrogen bonding. In the solid state, X-ray analysis shows that two urea molecules interact through only one hydrogen bond yielding infinite chains. This fact and the almost complete coplanarity of both the urea and the carbamate carbonyl groups determine the crystal packing to be formed by a parallel molecular arrangement. All these structural features are well supported by theoretical calculations that allow us to conclude that the formation of a network based on hydrogen bonding is energetically favourable. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2010.01.020
• 作为产物：
  描述：

  methyl hydrogen (-)-(1R,2S)-cyclobutane-1,2-dicarboxylate 在 三乙基硅烷 、 氯甲酸乙酯 、 三乙胺 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 丙酮 、 甲苯 为溶剂， 反应 17.5h， 生成 (1S,2R)-2-(((benzyloxy)carbonyl)amino)cyclobutane-1-carboxylic acid
  参考文献：
  名称：

  Stereoselective Synthesis of All Stereoisomers of Orthogonally Protected Cyclobutane-1,2-diamine and Some Chemoselective Transformations

  摘要：

  The four stereoisomers of protected cyclobutane-1,2-diamine have been prepared in an enantio- and diastereocontrolled manner through stereodivergent synthetic routes starting from a half-ester as a common chiral precursor. Orthogonal protection allows the chemoselective manipulation of both amino groups as shown in this work.

  DOI：

  10.1021/ol300689e

文献信息

• [EN] PROGRANULIN MODULATORS AND METHODS OF USING THE SAME<br/>[FR] MODULATEURS DE PROGRANULINE ET LEURS MÉTHODES D'UTILISATION
  申请人：ARKUDA THERAPEUTICS

  公开号：WO2021127303A1

  公开（公告）日：2021-06-24

  Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemperal lobe dementia (FTLD).

  本文提供了调节前蛋白颗粒素并在前颞叶痴呆等与前蛋白颗粒素相关疾病中使用这些化合物的方法。
• New compounds
  申请人：Zahn Stephan Karl

  公开号：US20090163467A1

  公开（公告）日：2009-06-25

  The present invention encompasses compounds of general formula (1) wherein R 1 , R 2 , R 4 , X, m, n and p are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物 其中 R 1 ，R 2 ，R 4 ，X，m，n和p的定义如权利要求书中所述 ，适用于治疗以细胞过度或异常增殖为特征的疾病，并且用于制备具有上述特性的药物组合物。
• (+)- and (−)-2-Aminocyclobutane-1-carboxylic Acids and Their Incorporation into Highly Rigid β-Peptides:  Stereoselective Synthesis and a Structural Study
  作者：Sandra Izquierdo、Federico Rúa、Abdelouahid Sbai、Teodor Parella、Ángel Álvarez-Larena、Vicenç Branchadell、Rosa M. Ortuño

  DOI：10.1021/jo0510843

  日期：2005.9.1

  Several derivatives of (+)- and (−)-2-aminocyclobutane-1-carboxylic acid, 1, have been prepared through enantiodivergent synthetic sequences. The stereoselective synthesis of free amino acid (+)-1 has been achieved, and this product has been fully characterized for the first time. Stereocontrolled alternative synthetic methodologies have been developed for the preparation of bis(cyclobutane) β-dipeptides

  通过对映异构的合成序列已经制备了（+）-和（-）-2-氨基环丁烷-1-羧酸1的几种衍生物。立体选择性合成游离氨基酸（+）- 1已实现，并且此产品已首次全面表征。已经开发了立体控制的替代合成方法以高产率制备双（环丁烷）β-二肽。其中，已经合成了对映体和非对映体。还已经制备了由环丁烷残基和线性氨基酸的偶联产生的β，β-和β，δ-二聚体。已经显示出环丁烷环作为单体和二聚体中的结构促进单元的能力。NMR结构研究和DFT理论计算证明了强分子内分子的形成氢键产生顺式[4.2.0]辛烷结构单元，在溶液和气相中均赋予这些分子高刚性。还观察到了由围绕氨基甲酸酯NC（O）键旋转引起的顺式-反式构象平衡的贡献，反式是主要的构象体。在固态中，不存在该平衡，此外，存在分子间氢键。
• [EN] CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'OREXINE CYCLOPENTAPYRROLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2022040058A1

  公开（公告）日：2022-02-24

  The present invention is directed to cyclopentapyrrole, furopyrrole and azabicycloheptane compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及环戊吡咯、呋喃吡咯和氮杂七环庚烷化合物，它们是促进晕睡素受体的激动剂。本发明还涉及所述化合物在潜在治疗或预防神经系统和精神障碍和疾病中的应用，这些疾病与晕睡素受体有关。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗这些与晕睡素受体有关的疾病中的应用。
• [EN] 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE<br/>[FR] DÉRIVÉS D'ACIDE 4-(2-FLUORO-4-MÉTHOXY-5-3-(((1-MÉTHYLCYCLOBUTYLE)MÉTHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL) CARBAMOYL)PHÉNOXY)-1-MÉTHYLCYCLOHEXANE-1-CARBOXYLIQUE ET COMPOSÉS SIMILAIRES COMME MODULATEURS DE RXFP1 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
  申请人：ASTRAZENECA AB

  公开号：WO2022122773A1

  公开（公告）日：2022-06-16

  The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl) carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as RXFP1 modulators for the treatment of heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The present invention also relates to crystalline forms of such compounds. An exemplary compound is e.g. (A).

  本发明涉及4-(2-氟-4-甲氧基-5-3-(((1-甲基环丁基)甲基)氨基)双环[2.2.1]庚烷-2-基)氨基苯氧基)-1-甲基环己烷-1-羧酸衍生物及类似化合物，其为RXFP1调节剂，用于治疗心力衰竭、保留射血分数的心力衰竭、中等射血分数的心力衰竭、降低射血分数的心力衰竭、慢性肾脏病和急性肾损伤。本发明还涉及这种化合物的晶体形式。一个示例化合物是例如(A)。